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Antiserum against tumor necrosis factor-alpha and a protease Inhibitor
reduce immune glomerular injury. Previous studies in this laboratory
have documented tumor necrosis factor alpha (TNF) release by mac-
rophage laden glomeruli in the accelerated autologous form of nephro-
toxic serum nephritis (AA-NTSN). We now report that the administra-
tion of anti-TNF antiserum to rats with the AA-NTSN reduces
albuminuria in a dose related manner (day 8 postinduction) and limits
glomerular necrosis (P < 0.05) without affecting the endogenous
creatinine clearance (Ccr). Protease inhibitors block cytolytic activity
of TNF in vitro and reduce glomerular necrosis in experimental
nephritis in vivo. The combined administration of anti-TNF antiserum
and an amidine-type protease inhibitor (BABIM) to rats with the
AA-NTSN caused a greater diminution of albuminuria and histopathol-
ogy than observed in rats treated with either agent alone, and also
prevented the fall in Ccr otherwise observed in this model system.
Since, in our studies, BABIM did not inhibit cytolytic TNF activity in
vitro, we conclude that the effects of combined administration of these
two agents are mediated by independent mechanisms. Our results
highlight the pathogenic significance of local TNF release in immune
renal disease accompanied by prominent glomerular macrophage accu-
mulation.
The pathogenesis of glomerular injury in experimental ne-
phritis induced by the injection of heterologous antiserum to the
glomerular basement membrane has been attributed to a broad
array of soluble inflammatory mediators. Thus, complement
components [1], coagulation factors [2], proteolytic enzymes [3,
4], oxygen radicals [5] and the myeloperoxide/hydrogen perox-
ide/halide system [6] all have been implicated in glomerular
injury during the neutrophil dependent, heterologous phase of
nephrotoxic serum nephritis. Conversely, glomerular injury
observed during the later, autologous phase of the disease
occurs in the absence of neutrophuls and complement and is
clearly dependent on local accumulation of mononuclear phago-
cytes [7]. Though macrophages are known to release a variety
of inflammatory mediators [8], the pathogenesis of macrophage-
dependent glomerulonephritis remains ill defined.
We have recently documented release of TNF by glomeruli
isolated from LEW rats with the AA-NTSN [9]. TNF initially
described as a macrophage product capable of inducing hemor-
rhagic necrosis of solid tumors [10], was subsequently shown to
be identical to cachectin, identified in sera of animals with
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chronic infections [11]. Numerous reports have appeared lately
to suggest that TNF is a potent inflammatory and immunoreg-
ulatory mediator. It stimulates procoagulant activity in vascular
endothelium [12], induces collagenase and prostaglandin secre-
tion by synovial cells [13], activates neutrophils [14] and
macrophages [15], enhances immune responses in vitro [15]and
in vivo [16]. More recently TNF has been shown to cause
vascular damage when injected in the skin of normal mice
together with bacteria in reaction dependent upon the fifth
component of complement [17].
In the present study we have administered anti-TNF antise-
rum to rats with the AA-NTSN, a model noted to be associated
with glomerular macrophage accumulation, to assess the role of
TNF in the pathophysiology of glomerular injury in this model
system. Further, since protease inhibitors are reported to
reduce cytotoxicity of TNF in vitro [18] and to mitigate glomer-
ular necrosis in experimental nephritis in vivo, possibly through
intreference with inflammatory mediators such as the plasma
contact system [19], additional studies have been performed to
determine whether the apparent beneficial effect of protease
antagonists in experimental nephritis could be linked to modu-
lation of TNF activity.
Methods
Animals
Inbred male LEW rats weighing 200 to 250 g were obtained
from Harlan Sprague-Dawley (Indianapolis, Indiana, USA) and
male New Zealand White rabbits (2 to 2.5 kg), from Cunipur
(St. Hyacinthe, Quebec, Canada).
Characterization of the experimental nephritis model under
study
The AA-NTSN was induced in LEW rats as previously
described [20]. Briefly, rats were immunized intraperitoneally
on day —5 with sheep immunoglobulin G (500 sg) emulsified in
0.5 ml of Complete Freund's Adjuvant (CFA). On day 0, a
subnephritogenic dose (0.05 ml) of sheep anti-rat glomerular
basement membrane (GBM) antiserum was administered
through the dorsal penile vein. This regimen induces prolifera-
tive endo- and extracapillary glomerulonephritis with focal
fibrin deposition, necrosis, focal disruption of the GBM and
occasional crescent formation. Immunofluorescence studies
reveal linear deposition of heterologous immunoglobulin along
the GBM. A transient neutrophil infiltration is noted on day 1
postinduction, to be replaced (day 2 to 3) by a prominent
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glomerular macrophage accumulation [7], and this latter phase
has been linked with the onset of proteinuria. Generally,
disease in this model system is self-limited, proteinuria so
induced falling to negligible levels within 10 to 12 days.
Antiserum against recombinant murine TNF-alpha (rMuTNF)
Rabbits were inoculated with 10 jig of rMuTNF (provided by
Dr. H.M. Shepard, Genentech Laboratories, San Francisco,
California, USA) emulsified in CFA at multiple subcutaneous
sites and two weeks later received 10 jig rMuTNF in Incom-
plete Freund's Adjuvant. Thereafter rabbits were boosted bi-
weekly with rMuTNF (10 jig) in phosphate buffered saline
(PBS) over a six month period. A test bleed was performed
prior to each injection and sera recovered were tested and/or
stored at —85°C.
Activity of anti-TNF antiserum was quantitated in immuno-
precipitation and neutralization assays. Briefly, rMuTNF was
radiolabelled to an activity of 4 X iO cpmlng (1251, New
England Nuclear, Boston, Massachusetts, USA) by the iodogen
method [21] and immunoprecipitated as described by Beutler,
Milsark and Cerami [22]. Antisera were serially diluted (1/1 to
1/10) in PBS containing 1% bovine serum albumin (BSA).
Twenty microliter aliquots were incubated with 0.2 ng 1251..
rMuTNF at 4°C for five hours. Thereafter, 10 jil of Staphylo-
coccus Protein A (ICN Immunobiologicals, Lisle, Illinois,
USA) diluted 1/5 with distilled water was added to each tube
and these incubated for further 30 minutes at room temperature.
Samples were then diluted with 1 ml PBS/l%-BSA, sedimented
in a Brinkmann microfuge, supernatants aspirated and the
radioactivity of pellets counted with a gamma spectrometer
(Tri-Carb, Packard).
Neutralizing activity of anti-rMuTNF antiserum was deter-
mined by quantitating inhibition of cytolysis of sensitive L929
cells effected by rMuTNF or by culture supernatants of glomer-
uli isolated from rats with AA-NTSN previously shown to
contain TNF [9]. In the latter instance glomeruli were isolated
from LEW on day 3 of the AA-NTSN by differential seiving [23]
and cultured 24 hours in RPMI 1640 medium in 80 cm2 flasks at
1000 glomeruli/mI. Recombinant MuTNF (10 pg/mI) and filtered
supernatants (125 jil) were preincubated (1 hr, room tempera-
ture) with serial dilutions of preimmune and immune anti-TNF
antisera and residual cytotoxic activity assessed in 96-well
plates, each well of which contained 3 x io L929 cells
prelabelled with 3H-methyl thymidine (10 jiCi/106 cells) in a
total volume of 250 jil of RPM! 1640, 10% FBS. After 72 hours
incubation (37°C, 100% humidity, 5% C02) 200 jil aliquots of
culture media were harvested and radioactivity counted in a
beta scintillation counter (Minaxi, Tri-Carb, Packard).
Isolation of the IgG fraction of anti-TNF antiserum
Ammonium sulfate precipitation, dialysis and gel filtration
(Sephadex G-200, Pharmacia Fine Chemicals, Dorval, Quebec,
Canada) were performed as described by Garvey, Cremer and
Sussdorf [24] to yield 6.4 mg IgG per ml of crude antiserum.
Albuminuria. Urinary albumin excretion was quantitated by
radial immunodiffusion assay [20]. Percent inhibition of albu-
minuria by various in vivo manipulations was calculated as
follows:
% inhibition = 100 x
[(mean albuminuria control rats —albuminuria of a rat treated
with inhibitor):mean albuminuna control rats]
Endogenous creatinine clearance. Serum and urine creati-
nine concentrations were determined with an autoanalyzer
(Astra, Beckman) and endogenous creatinine clearance (Ce,.,
mI/mm) calculated by dividing creatinine excretion (mg/mm) by
the plasma creatinine concentration (mg/mi).
Histology and immunofluorescence. Renal tissue was ex-
cised, blocks were cut and these were variously fresh frozen or
fixed either in 3.7% buffered formalin for light microscopy (LM)
or 2.5% glutaraldehyde for electron microscopy (EM). Three
micron sections of paraffin-embedded LM specimens were
stained with hematoxylin and eosin as well as periodic acid
silver-methyamine. Encoded slides were examined indepen-
dently by two pathologists (K.S. and S.J.) and the number of
glomeruli showing necrotic changes, fibrin deposition or cres-
cent formation determined as a percentage of at least 200
glomeruli examined on multiple widely separated sections.
Frozen tissue specimens were evaluated by direct immunoflu-
orescence using fluorescein isothiocyanate conjugated goat
anti-rabbit IgG F(ab)2 and C3, as well as goat anti-rat IgG
F(ab)2, C3 and 1gM (all from Organon Teknika, Scarborough,
Ontario, Canada). After rinsing in PBS (45 mm, 25°C) prepara-
tions were examined under UV epiillumination.
Assay of autologous rat anti-sheep antibody. Titers of circu-
lating antibody to sheep IgG were determined by solid phase
radiometric assay, as previously described [20], with sera
prediluted 1/64 in buffer.
Experimental design. The AA-NTSN was induced in nine
groups of rats according to the following protocol:
Experiments I and II. In each experiment 10 rats with the
AA-NTSN were randomly allocated to treatment (N = 5) and
control groups (N = 5). Two hundred microliters of anti-TNF or
nonimmune rabbit serum (NRS), diluted 1/4 with PBS, were
administered i.p., five hours prior to the intravenous injection
of sheep anti-GBM antiserum (day 0), and continued daily until
the end of experiment (day 8). Twenty-four hour urine collec-
tions were obtained on days 3 to 4 and 7 to 8 post-induction.
Rats were exsanguinated under ether anaesthesia on day 8 and
the sera recovered were retained for creatinine and anti-sheep
IgG measurements. Kidneys were excised for histopathological
studies as above.
Experiment ill. Increasing doses of anti-TNF antiserum were
administered to three groups of rats with the AA-NTSN (N =
5/group) as follows: Group A, 0.05 ml; B, 0.2 ml; C, 0.5 ml.
Control rats (N = 5, group D) were inoculated with 0.5 ml of
NRS on a daily basis.
Experiment IV. The IgG fractions of anti-TNF or NRS were
administered to rats daily (treatment and control groups, N =
5), commencing the day of nephritis induction and effects on
albuminuria/renal function assessed.
Experiment V. In order to determine whether the administra-
tion of crude NRS affected either the induction or course of the
AA-NTSN, NRS (0.2 ml diluted 1/4 in PBS) was given to 8 rats
with the AA-NTSN as above and subsequent albuminuna and
Cr compared to those observed in AA-NTSN rats receiving
saline alone (N = 8).
Experiments VI-VIJI. Additional studies were carried out to
assess the effects of a protease inhibitor in this model system.
BABIM [bis(5-amidino-2-benzimidazolyl)] ethane, a gift from
Richard R. Tidwell, PhD., University of North Carolina,
Chapel Hill, NC, USA] was administered to rats at a dose of 5
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mg/kg/day i.p., beginning day 1 after induction of the AA-
NTSN. Briefly, in three separate experiments anti-TNF antise-
rum, BABIM, anti-TNF antiserum + BABIM or NRS were
administered to four groups of rats (A-D, N =4/group, Exp. VI;
N = 5/group, Exp. Vil-Vill).
Experiment IX. The effect of anti-TNF and/or BABIM on
binding sheep anti-rat GBM antibody to renal tissue in vivo was
assessed as follows: Twenty-five rats were preimmunized with
sheep IgG on day —5 as per AA-NTSN induction and on day 0,
1 pg of '251-IgG anti-rat GBM (approximately iO cpm) in 0.2 ml
PBS 5% normal sheep serum was injected intravenously to five
groups variously treated with anti-TNF, BABIM, anti-TNF +
BABIM, NRS or PBS (N = 5/group). On day 3 animals were
exsanguinated, samples of kidney, liver and lung tissues ob-
tained, and specific activities determined using a gamma
counter.
Effect of BABIM on cytotoxic activity of rMuTNF in vitro
The cytotoxic activity of rMuTNF (10 pg/mI) on L929 cells
was assessed in 96-well plates essentially as described above, in
the presence or absence of BABIM (10—n M to 10 '°M). Briefly,
BABIM was dissolved in distilled water, filtered sterile and
dilutions were added to triplicate either to target cells in media
alone or to the cells incubated in presence of rMuTNF.
Statistical signflcance
Statistical significance was calculated using the Student's
t-test. Additionally, the Bonferroni Method, a simultaneous
multiple comparison procedure [25] was employed to assess
more adequately the significance of differences among experi-
mental groups in values of albuminuria and creatinine clear-
ances.
Results
Activity of anti-TNF antiserum
The precipitating and neutralizing activities of rabbit antisera
against rMuTNF in this study are illustrated in Figures 1 and 2,
respectively. Precipitating activity reached a peak at three
months after the initial immunization (50% precipitation at
approximately 1:8000 dilution) and subsequently declined. Con-
versely, neutralizing activity of such sera climbed to 50% with
a 1:4000 dilution at three months and increased thereafter with
repeated boosts to a titer of 1:32,000 at five months only to
remain at this level till the end of the study (Fig. 2A). As
illustrated in Figure 2B, the anti-TNF antiserum generated in
this study fully inhibited cytotoxic activity of culture superna-
tants of nephritic glomeruli at similar dilutions.
Effect of anti-TNF on albuminuria and Ce,.
As illustrated in Table 1 (Experiment 1), anti-TNF antiserum
significantly reduced albuminuria of rats with the AA-NTSN as
measured on days 3 to 4 and 7 to 8 following nephritis induction
(P < 0.0025 and P < 0.0005, respectively; mean suppression
day 3 to 4, 42.9% 17.4%; day 7 to 8, 53.6% 14.2%). This
reduction could not be attributed to a fall in glomerular filtration
in the anti-TNF group, since Cr on days 4 and 8 in both groups
were insignificantly different (day 4, anti-TNF, 0.66 0.10
ml/min; NRS 0.72 0.11 mI/mm; day 8, anti-TNF, 0.52 0.24
ml/min; NRS 0.51 0.19 mllmin; mean SD).
These results were confirmed in an additional experiment
(Exp. II) consisting of six treated and control nephritic rats
(data not shown). Overall suppression of albuminuria in these
experiments on days 3 to 4 and 7 to 8 were as follows: day 4,
46.8% 21.3%, day 8, 47.9% 23.9%, N = 11).
Dose dependent effect of anti-TNF in AA-NTSN
The effects of graded doses of anti-TNF antiserum (0.05 ml,
0.2 ml, 0.5 ml), administered daily, on albuminuria on day 8
following induction of the AA.NTSN were examined in Exper-
iment III. Administration of 0.05 ml antiserum reduced albu-
minuria 45%, but this effect was not significant due to the large
variability of the response. Conversely, albuminuria was re-
duced by 39.3% and 65.9% in rats treated with 0.2 ml and 0.5
mI/day, respectively, the higher dose being significantly more
effective. C. values were equivalent in all groups.
Effects of the IgG fractions of anti-TNF antiserum in the
AA-NTSN
The IgG fraction of anti-TNF was as effective as crude
antiserum in reducing albuminuria in AA-NTSN. Specifically,
albuminuria in rats (N = 5) receiving the IgG fraction of
anti-TNF antiserum was 120.3 20.4 mg/24 hours on day 8
postinduction (P < 0.05; percent suppression, 42.5% 9.9%).
Ccr, day 8, was unaffected by such treatment (Car, rats receiv-
ing the IgG fraction of anti-TNF antiserum, 1.06 0.15 mI/mm,
N = 5; rats treated with the IgG fraction of NRS, 0.86 0.13
mI/mm, N = 5, Exp. IV).
As an additional control we noted that Cr of rats with
AA-NTSN receiving daily injections of nonimmune rabbit
serum were equivalent to AA-NTSN rats receiving vehicle only
(PBS, N = 8) on both days 4 and 8 postinduction (Exp. V, data
not shown).
Effects of anti-TNF and BABIM on albuminuria/renal
function in the AA-NTSN
The combined administration of anti-TNF and BABIM
caused greater inhibition of albuminuria in the AA-NTSN than
obtained when these agents were given separately (Exp. VI,
Fig. 3A). Whereas in this single experiment reduction in albu-
minuria by anti-TNF or BABIM on day 8 did not reach
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Fig. 1. Precipitation of '251-rMuTNF by serialdilutions of preimmune
rabbit serum (....) and immune serum recovered at 2 months (—0—)
and 3 months (—•—) after the initial inoculation with rMuTNF.
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Fig. 2. A. Neutralizing activity of serial dilutions of anti-rMuTNF
antiserum assessed by quantitating suppression of cytotoxic activity of
rMuTNF (10 pg/mI) on 3H-thymidine labelled L929 cells. B. Neutrali-
zation of cytolytic activity of culture supernatants of glomeruli isolated
from rats with the AA-NTSN on day 3 postinduction, following
preincubation with serial dilutions of sera recovered from rabbits 5
months after the initial immunization with rMuTNF (0) of preimmune
rabbit serum (•). Percent of suppression of cytotoxicity was calculated
as follows: % suppression = 100 x E(mean cpm release by TNF/glom.
supematant — mean cpm by TNF/glom. supernatant after preincuba-
tion with immune/preimmune sera): mean cpm release by TNF/glom.
supernatant]
accepted level of statistical significance, possibly due to small
size of the groups so treated, pooled data from three such
experiments (VI to VIII) as shown in Figure 3B clearly docu-
ment that both anti-TNF and BABIM reduce albuminuria (day
8) when administered as a single agent: BABIM 46.9 28.5
mg/24 hrs, N = 14, anti-TNF 47.9 25.1 mg/24 hrs, N = 14;
NRS, 140.3 43.6 mg/24 hrs, N = 14; BABIM versus NRS and
anti-TNF versus NRS, Student's test, P < 0.0005; Bonferroni
Method, P <0.00014). The simultaneous multiple comparison
procedure (Bonferroni Method) was utilized in statistical eva!-
uation to control the error rate associated with the whole set of
comparisons. In each experiment a combination of anti-TNF
and BABIM caused a greater fall in albuminuria than did either
agent alone. In pooled data from these three experiments the
difference between anti-TNF and anti-TNF + BABIM groups
was significant, whereas the comparison between groups
treated with BABIM and anti-TNF + BABIM yielded P values
below the borderline of significance (Bonferroni Method, P <
0.04 and P < 0.08, respectively).
Albuminuria was reduced 78% by day 8 in AA-NTSN rats
treated with both anti-TNF antiserum and BABIM (N = 14).
As illustrated in Figure 4, AA-NTSN rats treated with
anti-TNF and BABIM demonstrated a striking preservation of
Cr on day 8 following nephritis induction, while Cr of rats
treated with anti-TNF or BABIM alone were equivalent to
NRS/PBS controls (Bonferroni Method, anti-TNF + BABIM
vs. NRS, P <0.00014; anti-TNF + BABIM vs. anti-TNF, P <
0.0004; anti-TNF + BABIM vs. BABIM, P < 0.00014). The
beneficial effect on C. obtained by administering these two
agents in concert was also demonstrable on day 4, though at this
time point the effect was less prominent (Ccr; anti-TNF +
BABIM vs. NRS 0.05 <P < 0.1; anti-TNF + BABIM vs.
anti-TNF P < 0.05).
Effect of BABIM on cytotoxicily of rMuTNF in vitro
BABIM was not toxic to the L929 cell line at concentrations
of l0— to 10— M in incubation periods of up to 72 hours. In the
present study even l0— M BABIM caused no notable suppres-
sion of cytolytic activity of rMuTNF in the system employed.
In these experiments BABIM was supplemented on a daily
basis to the original concentration in the well since this inhibitor
has been observed to loose activity in plastic.
Renal histopathology
Daily administration of anti-TNF and/or BABIM to rats with
the AA-NTSN did not prevent development of glomerular
hypercellularity, as observed in nephritic rats receiving NRS
vehicle (PBS). Conversely, glomerular necrosis, fibrin deposi-
tion and damage to the GBM were significantly reduced in the
AA-NTSN by both agents (Fig. 5, Table 2, anti-TNF vs. NRS,
P < 0.01; BABIM vs. NRS, P < 0.0025). Combined adminis-
tration of anti-TNF antiserum plus BABIM caused a more
striking reduction in these three parameters of renal injury than
observed with either agent in isolation, though in case of
BABIM the difference was not statistically significant (Table 2,
anti-TNF vs. anti-TNF + BABIM, P < 0.01; BABIM vs.
anti-TNF + BABIM, 0.05 <P < 0.1). BABIM was somewhat
more effective than anti-TNF antiserum (0.2 mI/day) in amelio-
rating glomerular necrosis (anti-TNF vs. BABIM, P < 0.02),
although equivalent results could have been obtained with a
higher dose of anti-TNF. Renal histopathology in rats with the
AA-NTSN treated with NRS was analogous to that observed in
rats treated with PBS alone, suggesting therefore, that the
administration of rabbit serum did not contribute to histologic
changes in AA-NTSN (incidence of glomerular necrosis: NRS
9.92% 4.99%, PBS 8.00% 4.65%; glomeruli with crescents:
NRS 2.33% 2.40%, PBS 2.37% 1.79%).
Crescent formation is not a prominent feature in this model
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Table 1. Effect of anti-rMuTNF antiserum on albuminuria (mg/24 hrs) in rats with the AA-NTSN
NRS controls anti-TNF treated
Animal
number Day 3—4 Day 7—8
Animal
number Day 3—4 Day 7—8
1
2
3
4
5
177.0
147.0
131.7
158.0
126.0
176.8
189.2
177.1
259.2
225.0
6
7
8
9
10
133.0
73.3
59.5
70.2
86.4
142.8
111.8
63.4
70.0
88.9
Mean SD 147.9 18.4 205.5 32.1 84.8 25.7 95.3 29.0
Abbreviations are: AA-NTSN, the accelerated autologous form of nephrotoxic serum nephritis; SD, standard deviation; NRS, non-immune
rabbit serum; anti-rMuTNF anti-serum, rabbit anti-serum to recombinant murine tumor necrosis factor-alpha with neutralizing titer of 1:32,000.
Day4 Day8
Fig. 3. A. Twenty-four hour albuminuria (mean SD of rats with the
AA-NTSN receiving anti-TNF antiserum (closed bars), BABJM
(hatched bars), combined treatment with anti-TNF and BABIM (Stip-
pled bars) or nonimmune rabbit serum (open bars) (N = 4/group).
Statistical significance of differences between experimental and control
groups is designated as follows: * < 0.05, < 0.00125. B. Pooled
results of three experiments (Exp. VI to VIII, mean SD) demonstrat-
ing the percent inhibition of 24-hour albumin excretion in the AA-
NTSN by anti-TNF andlor BABIM. The symbols are as indicated in A
except for the statistical significance: anti-TNF or BABIM vs. anti-TNF
+ BABIM: J1 < 0.05, < 0.0125, *p < 0.0025.
system. Few crescents are observed by day 8 postinduction.
Thus, though BABIM and/or anti-TNF antiserum tended to
reduce the frequency of crescents, some of these differences fail
to achieve statistical significance (Table 2, anti-TNF vs. NRS
and anti-TNF vs. BABIM, insignificant; BABIM vs. NRS, P <
0.025). Histologic analysis of renal sections of AA-NTSN rats
receiving the IgG fraction of anti-TNF antiserum revealed
decreased glomerular necrosis and fibrin deposition, consistent
with findings in rats treated with crude antiserum (data not
shown).
Fluorescence microscopy using FITC labelled goat anit-rat
IgG revealed bright linear fluorescence along the GBM of PBS
+
BABIM
Fig. 4. Measurements of endogenous creatinine clearance (mean
SD) in naive LEW (N = 6), experimental (anti-TNF, N = 11; BABIM,N = 13; anti-TNF + BABIM, N = 12) and control groups (NRS,
nonimmune rabbit serum, N = 13;PBS, N = 6)on day 8 after induction
of AA-NTSN. Data pooled from 2 experiments.
or NRS treated rats with the AA-NTSN. Identical findings were
obtained in rats injected with anti-TNF, BABIM or anti-TNF +
BABIM, as well as in rats treated with the IgG fraction of
anti-TNF. Representative renal sections of control (NRS) and
anti-TNF treated rats with the AA-NTSN were photographed
under UV epiilumination and are illustrated in Figure 6. Renal
sections of kidneys of all groups of rats treated with anti-TNF
antiserum stained with FITC labelled antibodies to rabbit IgG,
C3 were either negative, or revealed only faint granular stain-
ing. Analysis using fluorescent probes for rat 1gM and C3
displayed only weak granular staining, indicating that these
components of autologous rat serum did not considerably bind
to glomeruli of rats with AA-NTSN.
Electronmicroscopic studies failed to disclose significant
qualitative differences in glomerular histology. The principal
ultrastructural findings in treated and control AA-NTSN rats
were as follows: damage to the lamina rara interna, variable
fusion of epithelial foot processes as well as linear and granular
subepithelial (rarely subendothelial or mesangial) localization of
electron-dense deposits. EM documented equivalent location of
macrophages in experimental and control nephritic rats.
Assessment of the autologous rat anti-sheep IgG antibody
levels in experimental and control groups
Autologous antibody responses to sheep immunoglobulin G
in nephritic rats treated with anti-TNF and/or BABIM were
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Fig. 5. AA-NTSN in control rat receiving nonimmune rabbit serum is characterized by extensive glomerular necrosis with fibrin deposition (A),
absent from glomeruli of rats treated with anti-TNF antiserum (B). Light microscopy findings on BABIM-treated nephritic rats were virtually
indistinguishable from those receiving anti-TNF. In each case glomeruli are hypercellular (HE stain x 1000).
Table 2. Incidence of necrotic changes and early crescent formation
in renal gb meruli on day 8 (N = 200)
Glomeruli with
necrosis, GBM Glomeruli with
destruction and early crescent
fibrin deposition formation
Treatment % %
Non-immune rabbit 9.92 4.99 2.33 2.40
serum (NRS, N = 6)
Anti-TNF 3.63 1.83 1.00 1.16
antiserum (N = 8)
BABIM (N = 7) 1.21 0.89 0.43 0.53
Anti-TNF 0.10 0.22 0
antiserum + BABIM
(N=5)
Data were estimated from PAM-stained sections.
All cases had proliferative glomerulonephritis and there were no
significant differences in the degree of hypercellularity between groups.
assessed to determine whether the various treatment regimens
under study modulated the host humoral immune response, a
matter of some importance, since circulating antibody levels
have been shown to be closely correlated with glomerular injury
in this model system [20]. Anti-sheep antibody levels, measured
by solid phase radiometric assay on days 4 and 8 postinduction
AA-NTSN in treated and control rats, expressed as cpm, were
the following: day 4, anti-TNF antiserum treated 962 136, N
5; NRS 953 96, N = 5, (separate experiment) and day 8,
anti-TNF treated 994 291, N = 5; NRS 1097 118, N = 5
(Exp. VII). Anti-sheep IgG levels were identical even in ne-
phritic rats treated with a higher dose of anti-TNF antiserum
(0.5 ml/day), when compared to control animals receiving
equivalent amounts of NRS (anti-TNF 1100 74, N = 5; NRS
1097 118,N = 5, day 8, Exp. III). As expected, there were no
differences among control rats with the AA-NTSN receiving
PBS or NRS (PBS 805 78, N = 8; NRS 852 31, N = 8, Exp.
V).
Somewhat to our surprise, rats with AA-NTSN receiving
both anti-TNF and BABIM were found to have significantly
higher antibody levels than NRS controls on day 8 (anti-TNF +
BABIM1154±221,N5;NRS896± l0l,N=5;P<0.025;
Exp. VIII). In the same experiment anti-sheep IgG antibody
titers in anti-TNF or BABIM treated rats were equivalent to
control (anti-TNF 910 146, N = 5; BABIM 941 242, N =
5). Although, on day 4, antibody levels in anti-TNF + BABIM
treated AA-NTSN rats tended to be higher than the levels
measured in other groups, such differences were not statisti-
cally significant (data not shown).
Effects of anti-TNF and BABIM on binding sheep anti-rat
GBM antibody
Intravenously injected '251-IgG derived from sheep anti-rat
GBM antiserum demonstrated in preliminary experiments pref-
erential renal binding when compared to 1251-IgG recovered
from normal sheep serum (>10-fold). Accordingly, the effects
of BABIM and/or anti-TNF antibody on binding of '25I-IgG
o
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Fig. 6. Linear deposition of rat lgG along glomerular basement membranes of a respective control rat with AA-NTSN, treated with nonimmune
rabbit serum (A) and nephritic rat receiving rabbit anti-TNF antiserum (B). The intensity of staining is comparable (both pictures magnified X
1100).
from anti-GBM antiserum were investigated. Briefly, there
were no significant differences in binding radiolabelled IgG
between groups tested (anti-TNF 2277 520 cpm/g tissue,
anti-TNF + BABIM 2739 709, BABIM 2486 821, NRS
2061 256, PBS 2943 1260, N = 5 per group, Exp. IX).
Parallel measurements of liver and lung tissue yielded only
marginal counts, supporting the validity of this study (mean
SD for all groups: liver 363.4 128 cpm/g heart 160 45 cpmlg).
These data indicate that the various interventions employed in
this study did not interfere with the binding of heterologous
(sheep) immunoglobulin to the GBM, a pivotal event in disease
induction in this model system.
Discussion
Our results demonstrate that heterologous antiserum, neu-
tralizing cytotoxic activity of TNF in vitro, reduced glomerular
injury in vivo when administered to rats with the accelerated
autologous nephrotoxic serum nephritis. This is, to our knowl-
edge, the first direct evidence implicating TNF in the physio-
pathology of immune glomerulonephritis and the first successful
attempt to reduce intensity of a glomerular inflammatory reac-
tion with an antiserum against a soluble inflammatory mediator.
These data are, however, consistent with our previous obser-
vation that TNF is generated and released by glomeruli of
nephritic rats [9], the known pathogenic potential of this cyto-
kine [10—17] and the observation by Beutler et al [221 that an
antiserum against cachectin/TNF protects mice from lethal
effect of endotoxin-induced shock.
In the present study anti-TNF antiserum effected a dose-
dependent reduction in albuminuria without impairing glomer-
ular filtration. Histologic examination revealed a diminution in
glomerular necrosis and fibrin deposition, but no apparent effect
on the appearance of glomerular hypercellularity noted in this
model, indicating that monocyte recruitment to renal tufts was
not affected by systemic neutralization of TNF. Therefore,
although we cannot exclude a possibility that anti-TNF antise-
rum might have acted systemically, it is conceivable that it
operated primarily at the glomerular level to inhibit local
proinflammatory activity of this cytokine.
Moreover, we have documented that anti-TNF antiserum did
not affect levels of circulating antibody to sheep immunoglob-
ulin G and demonstrated that the intensity of glomerular depo-
sition of autologous antibody against the GBM-bound sheep
antiserum was the same in treated and control animals. In the
same light we have confirmed that rabbit anti-TNF antiserum
did not affect renal binding of sheep anti-rat GBM antibody in
vivo. We infer from these data that anti-TNF antiserum did not
modify humoral immune reactions bearing upon pathogenesis
of this nephritis model. Additional studies were performed to
document that the administration of crude rabbit serum did not
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modify immunopathogenic correlations in this model system.
Finally, we confirmed that identical reduction in glomerular
injury was observed when the IgG fraction of anti-TNF antise-
rum was administered to rats with the AA-NTSN to limit
delivery of exogenous proteins and exclude the possibility that
other factors present in sera of rabbits repeatedly inoculated
with rMuTNF might have affected our results.
We are uncertain which of the various proinfiammatory
activities ascribed to TNF was inhibited by the neutralizing
antiserum obtained in this study. A marked reduction in gb-
merular fibrin deposition (Table 2), consequent to anti-TNF
administration, may be due to interference with the TNF-
induced expression of procoagulant activity by endothelial cells
[12]. TNF has been reported to be directly toxic to vascular
endothelium [26], to augment cytotoxic activity of macrophages
[15] and stimulate production of proteolytic enzymes [13].
Clearly, modulation of any of these pathophysiologic processes
may be responsible for functional and histologic renal abnor-
malities in this model system.
We suggest, further to our previous report [9], that TNF may
be produced, at least in part, by monocytes/macrophages
infiltrating glomerular tufts. Indeed, an antimacrophage antise-
rum reduced glomerular mononuclear phagocyte infiltration and
abrogated renal injury in a passive autologous form of nephro-
toxic serum nephritis in rabbits [27]. Nonetheless, it is possible
that other cell types may be involved, as we have recently
accumulated evidence indicating that normal, contractile
mesangial cells spontaneously release TNF in culture (manu-
script submitted). Further, a resident population of mononu-
clear phagocytes has been identified in normal rat mesangium
[28] and this must be considered as a potential source of TNF.
The application of a protease inhibitor in this study was
inspired, at least in part, by the observation that only about 50%
of daily albumin losses were inhibitable by anti-TNF. Given the
evidence that neutral proteases may damage the GBM [29], we
set out to examine the possibility that protease inhibitor may
exert additive/synergistic effects on glomerular injury in the
AA-NTSN. An amidine-type synthetic antagonist (BABIM) of
proteolytic enzymes sharing trypsin-like properties was chosen,
since this compound has been shown to be safely and success-
fully used in vivo to ameliorate the course of immune complex-
mediated glomerular injury in mice [19]. Our results indicate
this protease inhibitor is capable of diminishing gbomerular
permeability to proteins in AA-NTSN to the degree comparable
to that of anti-TNF, although results of statistical analysis may
suggest that BABIM was somewhat more effective. It has also
reduced the intensity of glomerular necrotic changes similarly
to an immune complex nephritis model studied by Jennette et al
[19]. Indeed, the overall effects of anti-TNF antiserum and
BABIM on the progression of glomerular injury in the AA-
NTSN were virtually indistinguishable. There is no evidence in
support of a presumption that BABIM caused reduction in
albuminuria through a direct interference with enzymes digest-
ing GBM. It, however, seems conceivable that, given its
antinecrotic effect, BABIM might have exerted local inhibition
of serum proteolytic cascades generating kinins and activating
coagulation and fibrinolysis, as suggested by Jennette et al [19].
BABIM has potentiated the beneficial effect of anti-TNF on
proteinuria and renal histopathology. Moreover, both agents
applied in concert produced significant improvement of renal
function in rats with AA-NTSN. This phenomenon, not seen in
animals treated with anti-TNF or BABIM alone, indicates
apparent synergy of these two agents in abrogation of glomer-
ular inflammatory injury. Simultaneous administration of anti-
TNF and BABIM resulted in significant increase of serum
autologous nephritogenic antibody levels, an observation noted
exclusively in this experimental population. In fact, it has been
demonstrated in a previous report from this laboratory [20] that
serum autobogous antibody levels are, by day 8 of AA-NTSN,
inversely correlated with the magnitude of proteinuria, and this
is due to urinary losses of immunoglobulins. Hence, although
rat urine IgG was not measured in this study, we infer that the
elevated levels of antibody to heterologous (sheep) immuno-
globulin (day 8) further confirm the remarkable antiproteinuric
effect of combined therapy with anti-TNF and BABIM, rather
than indicating that antibody production is enhanced in these
animals.
The possibility that BABIM may mediate its beneficial effect
on AA-NTSN by directly inhibiting TNF activity was enter-
tained briefly, since other protease inhibitors (that is, TLCK)
have been reported to effectively protect established cell lines
from cytolysis by TNF [18]. Results of our tests indicate that
BABIM does not interfere with the cytotoxic activity of TNF in
vitro, and thus it seems unlikely that it might have directly
inhibited proinflammatory effects of TNF in vivo. The reasons
for the discrepancy between results of testing TNF sensitivity
to neutralization by protease inhibitors obtained by Ruggiero,
Johnson and Baglioni [18], and these presently reported are not
immediately obvious. Nonetheless a basic difference in exper-
imental design relying on target cell pretreatment with inhibitor
before adding TNF [18], opposed to coincubation of TNF and
inhibitor with target cells performed in our study, may be of
significant explanatory relevance. Additionally, even a slight
difference in sensitivity of target proteases to inhibition by
BABIM and other inhibitors employed by the Ruggiero group
might have resulted in a major discrepancy of the final effects.
Although the present report documents that TNF is an
important mediator of immune glomerular injury in at least this
model of experimental immune renal disease, it is clear that this
factor is but one of many soluble mediators involved in patho-
physiology of acute gbomerulonephritis. In this report we fur-
ther confirm the role of proteases in the pathogenesis of
experimental nephritis. Augmented release of arachidonic acid
metabolites have been found to be responsible for the early
decline in GFR in nephrotoxic serum nephritis [30]. Platelet
activating factor (PAF), another lipid derivative, have been
documented by ourselves and others [31, 32] to affect gbomer-
ular permselectivity to proteins and renal histology in the
AA-NTSN and other experimental nephritis models. It is of
note that TNF is reported to induce PAF release from endothe-
hal and other cell types [32] and therefore these two mediators
may be linked in the immune/inflammatory tissue injury. None-
theless, the present documentation of the participation of TNF
in the pathogenesis of experimental immune glomerulonephritis
clearly underlines the importance of further studies to elucidate
the exact mechanisms of TNF-induced tissue injury and to
delineate effective strategies to counter its pharmacologic ef-
fects.
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